Avneep Aggarwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Avneep Aggarwal has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Victor F. A. Almeida
Department of Anesthesiology, Cleveland Clinic Foundation, Cleveland, USA
2 shared publications - Alexander Avidan
Department of Anesthesiology, Critical Care and Pain Medicine, Hadassah Medical Organization and Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel
1 shared publication - Alexandre Lautrette
Medical Intensive Care Unit, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
1 shared publication - Ammar M. Lakda
From the Division of Anesthesiology Research, Department of Anesthesiology, Cleveland Clinic, Cleveland, Ohio
1 shared publication - Andra Ibrahim Duncan
From the Division of Anesthesiology Research, Department of Anesthesiology, Cleveland Clinic, Cleveland, Ohio
1 shared publication - Bara Ricou
Intensive Care of Geneva, Department of Anesthesiology, Pharmacology and Intensive Care, Geneva Hospital and University of Geneva, Switzerland
1 shared publication
Latest Publications
- 17 August 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
The TIMELESS Project: A Mixed-Methods Analysis of Modifiable Risk Factors and Transfusion Practices in 24,000 Cardiac Surgical Cases
BACKGROUND: Approximately 10% to 15% of all red blood cell (RBC) transfusions in the United States and United Kingdom occur during cardiac surgery. Despite efforts to standardize patient blood management, transfusion practices remain highly variable across providers and institutions. We launched the Transfusion Improvement to Minimizing Excess in Cardiac Surgery (TIMELESS) initiative to identify modifiable drivers of transfusion at our high-volume cardiac surgery center. METHODS: Our mixed-methods approach combined a retrospective data review and a survey to assess perioperative RBC and blood component (platelets, plasma, cryoprecipitate) transfusion through three key domains: (1) preoperative assessment/optimization (evaluation of modifiable risk factors for transfusion: preoperative anemia, malnutrition, anticoagulant/platelet inhibitor use); (2) perioperative blood conservation (modifiable risk factors: intraoperative antifibrinolytic use, hyperglycemia, perioperative hypothermia); (3) transfusion behaviors (laboratory guidance and transfusion triggers). These domains were investigated through (i) a retrospective database analysis that examined the association of risk factors with total intraoperative and early postoperative blood product transfusion in adult cardiac surgical patients between January 2018 and June 2024; and (ii) a structured front-line provider survey that examined opinions and behaviors that drive blood transfusion (including transfusion thresholds, triggers, and barriers to laboratory-guided practice) in anesthesia, surgical, and intensive care unit caregivers. RESULTS: Of 24,005 cardiac surgical patients in the database review, 13,420 (55.9%) received transfusions during surgery and/or early postoperatively. Of 258 front-line providers surveyed, 112 (43%) responded. Preoperative assessment/optimization (domain #1) and perioperative blood conservation (#2) found that five of six modifiable factors were associated with greater risk-adjusted transfusion: preoperative anemia (incidence rate ratio [IRR] 1.74, 95% confidence interval [CI], 1.67–1.83), malnutrition (IRR 1.44, 95% CI, 1.36–1.54), perioperative hypothermia (IRR 1.66, 95% CI, 1.59–1.73), and hyperglycemia (IRR 1.02 per 10 mg/dL, 95% CI, 1.02–1.02), whereas antifibrinolytic therapy was associated with reduced transfusion (IRR 0.90, 95% CI, 0.86–0.93). Transfusion triggers/laboratory guidance (#3) found that many transfusions were given empirically without laboratory-guidance (RBC 32.1%, platelets 44.9%, cryoprecipitate 55.0%, plasma 82.4%). Survey found that most providers (91/112, 81%) endorsed restrictive hemoglobin thresholds (<7.5 g/dL) for stable, non-bleeding patients; platelet and cryoprecipitate transfusion thresholds varied by specialty; laboratory-guidance was omitted for urgent bleeding/coagulopathy (99/112, 88%), prolonged surgical time (49/112, 44%), and long laboratory turnaround time (49/112, 44%). CONCLUSIONS: This large mixed-methods quality initiative identified modifiable risk factors, provider opinions, and transfusion behaviors to understand key drivers of transfusion in our cardiac surgery center. These results lay the groundwork to modify risk factors and transfusion behaviors and ultimately optimize perioperative blood transfusion therapy.
- 17 August 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
The TIMELESS Project: A Mixed-Methods Analysis of Modifiable Risk Factors and Transfusion Practices in 24,000 Cardiac Surgical Cases
BACKGROUND: Approximately 10% to 15% of all red blood cell (RBC) transfusions in the United States and United Kingdom occur during cardiac surgery. Despite efforts to standardize patient blood management, transfusion practices remain highly variable across providers and institutions. We launched the Transfusion Improvement to Minimizing Excess in Cardiac Surgery (TIMELESS) initiative to identify modifiable drivers of transfusion at our high-volume cardiac surgery center. METHODS: Our mixed-methods approach combined a retrospective data review and a survey to assess perioperative RBC and blood component (platelets, plasma, cryoprecipitate) transfusion through three key domains: (1) preoperative assessment/optimization (evaluation of modifiable risk factors for transfusion: preoperative anemia, malnutrition, anticoagulant/platelet inhibitor use); (2) perioperative blood conservation (modifiable risk factors: intraoperative antifibrinolytic use, hyperglycemia, perioperative hypothermia); (3) transfusion behaviors (laboratory guidance and transfusion triggers). These domains were investigated through (i) a retrospective database analysis that examined the association of risk factors with total intraoperative and early postoperative blood product transfusion in adult cardiac surgical patients between January 2018 and June 2024; and (ii) a structured front-line provider survey that examined opinions and behaviors that drive blood transfusion (including transfusion thresholds, triggers, and barriers to laboratory-guided practice) in anesthesia, surgical, and intensive care unit caregivers. RESULTS: Of 24,005 cardiac surgical patients in the database review, 13,420 (55.9%) received transfusions during surgery and/or early postoperatively. Of 258 front-line providers surveyed, 112 (43%) responded. Preoperative assessment/optimization (domain #1) and perioperative blood conservation (#2) found that five of six modifiable factors were associated with greater risk-adjusted transfusion: preoperative anemia (incidence rate ratio [IRR] 1.74, 95% confidence interval [CI], 1.67–1.83), malnutrition (IRR 1.44, 95% CI, 1.36–1.54), perioperative hypothermia (IRR 1.66, 95% CI, 1.59–1.73), and hyperglycemia (IRR 1.02 per 10 mg/dL, 95% CI, 1.02–1.02), whereas antifibrinolytic therapy was associated with reduced transfusion (IRR 0.90, 95% CI, 0.86–0.93). Transfusion triggers/laboratory guidance (#3) found that many transfusions were given empirically without laboratory-guidance (RBC 32.1%, platelets 44.9%, cryoprecipitate 55.0%, plasma 82.4%). Survey found that most providers (91/112, 81%) endorsed restrictive hemoglobin thresholds (<7.5 g/dL) for stable, non-bleeding patients; platelet and cryoprecipitate transfusion thresholds varied by specialty; laboratory-guidance was omitted for urgent bleeding/coagulopathy (99/112, 88%), prolonged surgical time (49/112, 44%), and long laboratory turnaround time (49/112, 44%). CONCLUSIONS: This large mixed-methods quality initiative identified modifiable risk factors, provider opinions, and transfusion behaviors to understand key drivers of transfusion in our cardiac surgery center. These results lay the groundwork to modify risk factors and transfusion behaviors and ultimately optimize perioperative blood transfusion therapy.
- 4 August 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (8) , 2160-2161
Toward Bedside-Ready Artificial Intelligence in Resuscitation: Low-Resolution, High-Value Signals
Was not provided for this article.
- 4 August 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (8) , 2160-2161
Toward Bedside-Ready Artificial Intelligence in Resuscitation: Low-Resolution, High-Value Signals
Was not provided for this article.
- 16 July 2026
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 145 (3) , 797-798
Maintaining Rigor in Language Model Studies: Comment
Was not provided for this article.
- 16 July 2026
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 145 (3) , 797-798
Maintaining Rigor in Language Model Studies: Comment
Was not provided for this article.
- Open Access
- 16 March 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (4) , 701-714
Influence of Age in End-of-Life Practices in Worldwide ICUs (ETHICUS-2): A Prospective Observational Study
OBJECTIVES: The practice of limiting life-sustaining therapy (LST) at end-of-life is widespread globally. The goal of this study was to evaluate whether patient’s age influences end-of-life limitations overall and of various LST in ICUs worldwide. DESIGN: Multinational, multicenter, prospective observational study. SETTING: One hundred ninety-nine ICUs in 36 countries worldwide. PATIENTS: Consecutive adult patients admitted to ICUs who died and/or had LST limitations (withholding, withdrawing, or active shortening of the dying process) were included during a 6-month period between September 2015 and September 2016. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Patients were grouped: younger than 65 years, 65–79 years old, and 80 years old or older. A total of 12,200 patients were included. In multivariate logistic regression analysis, odds ratio (OR) for any LST limitation in the 80 years old or older group was higher than in younger than the 65 years old group (OR 1.47 [95% CI, 1.22–1.76], p < 0.001). When stratified by region, this association was significant in Central and Southern Europe (OR 1.56 [95% CI, 1.11–2.20], p = 0.037 and OR 2.23 [95% CI, 1.58–3.17], p < 0.001, respectively), but not in the other regions. The proportion of withholding therapy of each LST was highest in the group of individuals 80 years or older, whereas the proportion of withdrawing therapy was highest in the group younger than 65 years. The 80-year-old or older group also had a shorter time from ICU admission to first limitation. The predominant reason for any LST limitation in all age groups was unresponsiveness to maximal therapy, followed by neurologic and chronic diseases. Patient age was rarely the primary reason for limitations for all groups. CONCLUSIONS: End-of-life limitations were higher in patients 80 years or older compared to those 65 years old or younger, with regional variations. The main reasons for limitations were comparable across age groups, with age not being the primary reason.
- 16 March 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (4) , 701-714
Open AccessInfluence of Age in End-of-Life Practices in Worldwide ICUs (ETHICUS-2): A Prospective Observational Study
OBJECTIVES: The practice of limiting life-sustaining therapy (LST) at end-of-life is widespread globally. The goal of this study was to evaluate whether patient’s age influences end-of-life limitations overall and of various LST in ICUs worldwide. DESIGN: Multinational, multicenter, prospective observational study. SETTING: One hundred ninety-nine ICUs in 36 countries worldwide. PATIENTS: Consecutive adult patients admitted to ICUs who died and/or had LST limitations (withholding, withdrawing, or active shortening of the dying process) were included during a 6-month period between September 2015 and September 2016. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Patients were grouped: younger than 65 years, 65–79 years old, and 80 years old or older. A total of 12,200 patients were included. In multivariate logistic regression analysis, odds ratio (OR) for any LST limitation in the 80 years old or older group was higher than in younger than the 65 years old group (OR 1.47 [95% CI, 1.22–1.76], p < 0.001). When stratified by region, this association was significant in Central and Southern Europe (OR 1.56 [95% CI, 1.11–2.20], p = 0.037 and OR 2.23 [95% CI, 1.58–3.17], p < 0.001, respectively), but not in the other regions. The proportion of withholding therapy of each LST was highest in the group of individuals 80 years or older, whereas the proportion of withdrawing therapy was highest in the group younger than 65 years. The 80-year-old or older group also had a shorter time from ICU admission to first limitation. The predominant reason for any LST limitation in all age groups was unresponsiveness to maximal therapy, followed by neurologic and chronic diseases. Patient age was rarely the primary reason for limitations for all groups. CONCLUSIONS: End-of-life limitations were higher in patients 80 years or older compared to those 65 years old or younger, with regional variations. The main reasons for limitations were comparable across age groups, with age not being the primary reason.